GlobalData, the industry analysis specialist, has released its new report, “Non-Small Cell Lung Cancer (NSCLC) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Non-Small Cell Lung Cancer (NSCLC) therapeutics market. The report identifies the key trends shaping and driving the global NSCLC therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NSCLC sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global Non-Small Cell Lung Cancer (NSCLC) therapeutics market was valued at $4.1 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.2% for the next eight years to reach $6.1 billion by 2017. This high growth forecast is primarily attributed to the strong pipeline landscape, population growth and release of new first-in-class drugs with better safety and efficacy profiles. Low treatment seeking, diagnosis and prescription rates and the availability of generics with better efficacy and safety profiles, pose significant challenges for prospective market entrants.
The report provides information on the key drivers and challenges of the NSCLC therapeutics market. Its scope includes:
- Annualized global NSCLC therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Tyrosine kinase inhibitor, microtubules, protein kinase inhibitors, cell division inhibitors, ERBB3 antagonist, DNA and RNA synthesis inhibitors, C-Met or ALK inhibitors, glutathione S-transferase binders, growth and survival of multiple myeloma (MM) cells inhibitors, HER2 dimerization inhibitors, antiangiogenesis inhibitors, COX-2 inhibitors, Pan Bcl-2 inhibitors and MUC1 tumor-associated antigens.
- Analysis of the current and future competition in the global NSCLC therapeutics market. Key market players covered are F. Hoffmann-La Roche Ltd/Genentech, Inc., Pfizer Inc., Novartis AG, Sanofi-aventis, Boehringer Ingelheim, Eli Lilly/Imclone Inc and Abraxis BioScience.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the NSCLC therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NSCLC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NSCLC therapeutics market landscape? - Identify, understand and capitalize.